

## References

I-120

1. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017;18(3):312-322.
2. Algazi A, Tsai K, Shoushtari A, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer*. 2016;122(21):3344-3353.
3. Doi T, Piha-Paul S, Jalal S, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. *J Clin Onco*. 2018;36(1):61-67.
4. Bordoni R, Ciardiello F, von Pawel J, et al. Patient-reported outcomes in OAK: A phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2018;19(5):441-449.
5. Horn L, Mansfield A, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive stage small-cell lung cancer. *N Engl J Med*. 2018;379:2220-2229.
6. Bauml J, Seiwert T, Pfister D, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. *J Clin Oncol*. 2017;35(14):1542-1549.
7. Chen R, Zinzani P, Fanale M, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed refractory classic Hodgkin lymphoma. *J Clin Oncol*. 2017;35(19):2125-2132.
8. Ott P, Elez E, Hirt S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. *J Clin Oncol*. 2017;35(34):3823-3829.
9. Grob J, Gonzalez R, Basset-Seguín N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm Phase II trial (KEYNOTE-629). *J Clin Oncol*. 2020;38(25):2916-2925.
10. Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*. 2020;395(10240):1835-1844.
11. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum—etoposide versus platinum—etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. *The Lancet*. 2019;394(10212):1929-1939.
12. Kato K, Chul Cho B, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. *The Lancet Oncol*. 2019;20(11):1506-1517.

13. Migden M, Rischin D, Schmults C, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med.* 2018;379(4):1-10.
14. Antonia S, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med.* 2017;377(20):1919-1929.
15. Chung H, Ros W, Delord J, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. *J Clin Oncol.* 2019;37(17):1470-1478.
16. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (Impower010): A randomized, multicentre, open-label, phase 3 trial. *The Lancet.* 2021;398(10308):1344-1357.
17. Patnaik A, Weiss G, Rasco D, et al. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: A dose-escalation phase 1 trial. *Cancer Chemother Pharmacol.* 2022;89(1):93-103.
18. Kelly R.J, Kuzdzal A, Zanter T, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med.* 2021;384(13):1191-1203.
19. Bajorin D.F, Witjes J.A, Gschwend M, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *N Engl J Med.* 2021;384(22):2102-2114.
20. Tawbi H, Schadendorf D, Lipson E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. *N Engl J Med.* 2022;386(1):24-34.
21. Vuky J, Balar A, Castellano D, et al. Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. *J Clin Oncol.* 2020;38(23):2658-2666.
22. Cortes J, Cescon D, Rugo H, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (KEYNOTE-355): A randomized, placebo-controlled, double-blind, phase 3 clinical trial. *The Lancet.* 2020;396(10265):1817-1828.
23. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. *N Engl J Med.* 2021;385(20):1856-1867.
24. Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med.* 2022;386(5):437-448.
25. Marabelle A, Le D, Ascierto P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. *J Clin Oncol.* 2020;38(1):1-10.
26. Motzer R, Alekseev B, Rha S, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med.* 2021;384(14):1289-1300.

27. Luke J, Ascierto P, Carlin M, et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. *Future Oncol.* 2020;16(3):4429-4438.
28. Andre T, Shiu K, Kim T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med.* 2020;383(3):2207-2218.
29. Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. *J Clin Oncol.* 2020;38(14):1505-1517.
30. Oh D, He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. *NEJM Evid.* 2022;1(8).
31. Doki Y, Ajani J, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. *N Engl J Med.* 2022;386:449-462.
32. Ghassan K, Chan S, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. *J Clin Oncol.* 2022;40(4):379.
33. Johnson M, Cho B, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. *J Clin Oncol.* 2022;JCO2200975.
34. O'Brien M, Paz-Ares, L, Marreaud S et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage Ib-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol.* 2022; 23(10): 1274-1286.
35. Mai H, Chen Q, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. *Nat Med.* 2021; 27(9):1536-1543.
36. Atezolizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 18, 2021.
37. Avelumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 5, 2018.
38. Cemiplimab-rwlc In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 26, 2019.
39. Durvalumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated September 30, 2019.
40. Nivolumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 7, 2019.

41. Pembrolizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 7, 2019.
42. Dostarlimab-gxly In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 18, 2022.
43. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Atezolizumab.
44. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Avelumab.
45. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Cemiplimab-rwlc.
46. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Dostarlimab-gxly.
47. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Durvalumab.
48. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Nivolumab.
49. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Nivolumab;Relatlimab.
50. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Pembrolizumab.
51. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Retifanlimab.
52. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Toriplamab.
53. Micromedex DrugDex Compendium®. 2023. Atezolizumab.
54. Micromedex DrugDex Compendium®. 2023. Avelumab.
55. Micromedex DrugDex Compendium®. 2023. Cemiplimab-rwlc.
56. Micromedex DrugDex Compendium®. 2023. Dostarlimab-gxly.
57. Micromedex DrugDex Compendium®. 2023. Durvalumab.
58. Micromedex DrugDex Compendium®. 2023. Nivolumab.
59. Micromedex DrugDex Compendium®. 2023. Pembrolizumab.
60. Micromedex DrugDex Compendium®. 2023. Retifanlimab.
61. National Comprehensive Cancer Network (NCCN). Atezolizumab. NCCN Drugs and Biologics Compendium®. 2023.
62. National Comprehensive Cancer Network (NCCN). Avelumab. NCCN Drugs and Biologics Compendium®. 2023.
63. National Comprehensive Cancer Network (NCCN). Atezolizumab. NCCN Drugs and Biologics Compendium®. 2023.

64. National Comprehensive Cancer Network (NCCN). Cemiplimab-rwlc. NCCN Drugs and Biologics Compendium®. 2023.
65. National Comprehensive Cancer Network (NCCN). Dostarlimab-gxly. NCCN Drugs and Biologics Compendium®. 2023.
66. National Comprehensive Cancer Network (NCCN). Durvalumab. NCCN Drugs and Biologics Compendium®. 2023.
67. National Comprehensive Cancer Network (NCCN). Nivolumab. NCCN Drugs and Biologics Compendium®. 2023.
68. National Comprehensive Cancer Network (NCCN). Pembrolizumab. NCCN Drugs and Biologics Compendium®. 2023.
69. National Comprehensive Cancer Network (NCCN). Retifanlimab. NCCN Drugs and Biologics Compendium®. 2023.
70. Tecentriq® (atezolizumab) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 12/2022.
71. Bavencio® (avelumab) injection, for intravenous use [package insert]. EMD Serono, Inc. Rockland, MA. Revised 07/2022.
72. Libtayo® (cemiplimab-rwlc) injection, for intravenous use [package insert]. Regeneron Pharmaceuticals Inc. Tarrytown, NY. Revised 11/2022.
73. Jemperli® (dostarlimab-gxly) injection, for intravenous use [package insert]. GlaxoSmithKline. Research Triangle Park, NC. Revised 07/2023.
74. Imfinzi® (durvalumab) injection, for intravenous use [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. Revised 11/2022.
75. Opdivo® (nivolumab) injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 10/2023.
76. Opdualag™ (nivolumab and relatlimab-rmbw) injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 03/2022.
77. Keytruda® (pembrolizumab) injection, for intravenous use [package insert]. Merck & Co., Inc. Whitehouse Station, NJ. Revised 01/2024.
78. Zynyz™ (retifanlimab-dlwr) injection, for intravenous use [package insert]. Incyte Corporation. Wilmington, DE. Revised 03/2023.
79. Loqtorzi™ (toripalimab-tpzi) injection, for intravenous use [package insert]. Coherus BioSciences, Inc. Redwood City, CA. Revised 10/2023.